Latest Conference Articles

In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.

Eileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.

Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.

The future of minimal residual disease testing in chronic lymphocytic leukemia may be applicable for patients being treated with venetoclax in combination with Bruton’s tyrosine kinase inhibitors.

During the NCCN 2021 Congress: Hematologic Malignancies Natalie S. Callander, MD, discusses treatment options in relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Alice S. Mims, MD, discussed targeting biomarkers in acute myeloid leukemia, and upfront disease management.

During the NCCN 2021 Congress: Hematologic Malignancies, Aaron T. Gerds, MD, MS, explained the risk stratification tools used in patients with myeloproliferative neoplasms.

Alice S. Mims, MD a hematologist at The Ohio State University Comprehensive Cancer Center, discusses testing and actionable mutations in newly diagnosed acute myeloid leukemia.

The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.

Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.

In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.

In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.

In patients with estrogen receptor–positive, HER2-negative early breast cancer, giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole.

Blood-based tumor mutational burden was hypothesized to be predictive of benefit on atezolizumab treatment in patients with non–small cell lung cancer, but a study has shown otherwise.

Jesús García-Foncillas, MD, PhD, discusses the rationale behind comparing the efficacy of larotrectinib and entrectinib head-to-head in patients with metastatic solid tumors with neurotrophic gene fusions.

Results from the MRTX-500 trial show that sitravatinib administered in combination with nivolumab can elicit durable response and lead to robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.

Exploratory results from the phase 3 IMpower010 trial look positive fo the use of adjuvant atezolizumab in various non–small cell lung cancer populations.

Among patients with malignant pheochromocytoma and paraganglioma, treatment with sunitinib demonstrated improved efficacy.

Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.

Data from the phase 1/2 KRYSTAL-1 study presented at the 2021 ESMO congress showed promising clinical activity with adagrasib in treating previously treated patients with KRASG12C-mutated colorectal cancer.

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

The combination of nivolumab/ipilimumab did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal cancer.

In patients with high-risk nonmetastatic prostate cancer treatment involving abiraterone acetate and prednisolone with or without enzalutamide added to androgen deprivation therapy for 2 years led to meaningfully enhanced survival outcomes.

In patients with metastatic castration resistant prostate cancer, sabizabulin was well tolerated and associated with significant and durable objective tumor responses

Clinically effective results in a group of patients with HRD-positive, chemotherapy-naïve metastatic castration resistant prostate cancer was induced with nivolumab plus rucaparib.

In the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, the combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone.

In patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations, datopotamab deruxtecan, an antibody drug conjugate, demonstrated safe antitumor activity.

Progression-free survival after [vic]-trastuzumab duocarmazine treatment in patients with pretreated, metastatic HER2-positive breast cancer was improved compared with physician’s choice chemotherapy.

According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.